Role of cyclooxygenase-2 in the carcinogenesis of gastrointestinal tract cancers: A review and report of personal experience

doi:10.3748/wjg.v12.i9.1336

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 9

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4594)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series, Tables (1-3) series.

Item

Count

PDF

402

HTML

3575

Figures (1-4)

304

Tables (1-3)

313

Sum=4594

Mar 7, 2006 (publication date) through Feb 7, 2025

Times Cited of This Article

Times Cited (58)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Mar 7, 2006; 12(9): 1336-1345
Published online Mar 7, 2006. doi: 10.3748/wjg.v12.i9.1336

Table 1 Selective COX-2 inhibitors (coxibs) and chemoprevention in gastrointestinal tract tumors

Generic name	Brand name	PhCo^b	Esophagus				Stomach			Colorectum
			Cancer cell line	CIA^c	reflux-induced animal	Human (BE^d)	Cancer cell line	CIA^c	MIA^e	Cancer cell line	CIA^c	MIA^e	Human (FAP^f)
Tricyclic
Celecoxib	Celebrex	Pfizer			(23)			(46,47)	(75)	(76,77)	(81,82)	(54)	(56)
MF-tricyclic	EC^a	Merck			(21)							(53,87)
Rofecoxib	Vioxx	Merck				(24)						(55)
Tilmacoxib	Japan Tobacco			(20)						(78)		(88,89)
Valdecoxib Bextra	Pfizer
EtoricoxibArcoxia	Merck
Methanesulphonamide
NS-398	EC^a	Taisho	(18,19,70,71)				(44,45,72)		(49)	(72)	(83)
Nimesulide	Mesulid	Helsinn					(73)	(48)			(84)	(90)
Flosulide			Schering	(70)
Others
Nabumetone	Relafen	Glaxo Smith Kline									(85)	(91)
Meloxicam	Mobic	Boehringer Ingelheim								(79,80)	(86)
Etodolac	Lodine	Wyeth					(74)			(74)
Lumiracoxib	Prexige	Novartis

ECa, experimental compound; PhCob, Pharmaceutical company; CIAc, carcinogen-induced animal; BEd, Barrett's esophagus; MIAe, mutation-induced animal; FAPf, familial adenomatous polyposis; Numbers in parentheses show reference numbers

Citation: Fujimura T, Ohta T, Oyama K, Miyashita T, Miwa K. Role of cyclooxygenase-2 in the carcinogenesis of gastrointestinal tract cancers: A review and report of personal experience. World J Gastroenterol 2006; 12(9): 1336-1345
URL: https://www.wjgnet.com/1007-9327/full/v12/i9/1336.htm
DOI: https://dx.doi.org/10.3748/wjg.v12.i9.1336